Comprehensive Analysis On United Kingdom Cystic Fibrosis Therapeutics Market 2023 With Future Trend, Market Size, Business Growth, Top Key players, CAGR

UK Cystic Fibrosis (CF) Therapeutics market

Report Overview

The UK Cystic Fibrosis (CF) Therapeutics market size stood at around USD 0.020 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Cystic Fibrosis (CF) is an inherited disease caused by a faulty version of a gene known as CFTR. The gene and the protein help control the movement of salt and water in and out of cells. When the gene is faulty, it can cause thicker mucus, thus lungs the major affected body organ; over time this thick mucus blocks and damages airways, leading to infections and making it hard to breathe. People with CF may also develop other problems, such as liver disease or CF-related diabetes (CFRD). Around 85%of people with CF also have difficulty digesting food.

According to UK Cystic Fibrosis Registry, in 2019, around 10655 CF patients have registered; more than 60% of the population are aged 16 or over and 21 is the median age of the UK CF population. Around 30% of the patient are diagnosed by New-born Screening (NBS). Of the 114 people with CF who died in 2019, the median age at death was 31 years old.

Market Growth Drivers

The prevalence of Cystic Fibrosis (CF) is considered a major driving factor in the UK market as around 10655 CF patients have been registered in 2019. Thus, the rising prevalence of respiratory problems, GI complications, and reproductive disorders in patients with CF is also expected to boost the demand for the treatment of disease during the forecast period.

The emergence of drugs that are targeting the defect in cells of people suffering from CF is enhancing market growth during the forecast period. In addition to this, many potential candidates are in their final stages of development and are projecting the growth of the market in the near future. For instance, Vertex Pharmaceuticals Inc. announced positive results from their phase III clinical study on inhaled mannitol indicated for the treatment of mucociliary clearance.

Along with this, the increasing incidence of chronic cough, blood in sputum, & collapsed lungs, and the technologically advanced devices used for various serious cases such as airway clearance techniques, mucous thinners, and others also propelling the CF therapeutics market during the forecast period.

The sudden outbreak of the COVID-19 pandemic brings the patient is at high risk of being infected by the virus. This, coupled with other various complications such as lung infections, inflammation of the pancreas, CF-related diabetes, and others strongly augmenting the CF market growth during the forecast period.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/139896/

Top Major Players

Major key players operating in UK Cystic Fibrosis (CF) markets are Vertex Pharmaceuticals Incorporated, AbbVie Inc., Novartis AG, Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, and others. Four branded drugs; Kaftrio (triple combination therapy), Symkevi, Kalydaco, and Orkambi currently marketed by Vertex Pharmaceuticals Incorporated are the best medication drugs trusted by over 90% of the patients affected by cystic fibrosis in the UK will foster the market share during the forecast period.

The United Kingdom Cystic Fibrosis Therapeutics Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global United Kingdom Cystic Fibrosis Therapeutics market. This report explores all the key factors affecting the growth of the global United Kingdom Cystic Fibrosis Therapeutics market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On United Kingdom Cystic Fibrosis Therapeutics Market @ https://www.prudentmarkets.com/sample-request/139896/

Market Segmentation

By Antibiotics:

On the basis of antibiotics, the cystic fibrosis treatment market has been categorized into

Intravenous (IV) Antibiotics
Inhaled Antibiotics
Long-term Azithromycin use
Prophylactic Flucloxacillin use
Others

IV antibiotics are given to the patient through their veins. This treatment can take a number of days and might take place as a hospital inpatient, or at home. The proportion of patients receiving at least one IV course at home was 23.1% and in-hospital was 38.0%. About 90% of people chronically infected with Pseudomonas aeruginosa should be prescribed at least one of the inhaled antibiotics (Colistin, Promixin, Aztreonam, Tobramycin). Azithromycin is an antibiotic with some anti-inflammatory properties. It is recommended for long-term use as a prophylactic antibiotic in people with chronic Pseudomonas aeruginosa.

By Muco-active Therapies:

In terms of muco-active therapies, the cystic fibrosis treatment market has been classified into

Mannitol
DNase
Hypertonic Saline
Burden of Treatment
Others

This treatment helps to thin mucus so that it is easier to cough out of the body. In the UK, about 36.8% of people are on hypertonic saline or mannitol. And 67.6% of people are on DNase.

By Bronchodilators and Steroids:

In terms of bronchodilators and steroids, the cystic fibrosis treatment market has been divided into

Inhaled Bronchodilators
Inhaled Corticosteroids
Others

Bronchodilators and corticosteroids targeted the beta-2 receptor, activates it, and relax the airway smooth muscles. In the UK, around 10655 CF patients have been registered, out of which around 60% patients solely on inhaled bronchodilators and the rest on inhaled cortico-steroids and the combination therapy.

By Other Therapies:

Based on other therapies, the cystic fibrosis treatment market has been classified into

CFTR modifiers
Physiotherapy
Transplants
Others

As of 2019, Ivacaftor was approved for use on the NHS across the UK for people aged one year and older with at least one copy of 9 specified CFTR ‘gating’ mutations, and for people aged 18 and over with the R117H mutation. In June 2020, the marketing authorization was extended to cover anyone aged 6 months and over with the R117H mutation. Lumacaftor/Ivacaftor is licensed for use in patients aged 2 years and over with two copies of the F508del mutation. Tezacaftor/Ivacaftor is licensed for use in patients aged 12 and over who have two copies of the F508del mutation, or a single copy of F508del and one of 14 specified ‘residual function’ mutations. Elexacaftor/Tezacaftor/Ivacaftor is accessible through a named patient access scheme to eligible individuals who are critically ill. 13 people with cystic fibrosis in the UK are recorded as having received Elexacaftor/Tezacaftor/Ivacaftor in 2019

By Route of Administration:

In terms of route of administration, the cystic fibrosis treatment market has been segmented into

Oral
Parenteral
Others

The parenteral route of administration which includes inhaled and injections holds the largest market share owing to the speedy recovery of cystic fibrosis. Also, the oral route of administration also fosters the cystic fibrosis market share; for example, the development of CFTR drugs.

By Distribution Channel:

Based on the distribution channel, the cystic fibrosis treatment market is classified into
Retail pharmacies
Drug stores
Hospital pharmacies
Online pharmacies
Others

Retail pharmacies and drug stores are anticipated to dominate the market. But due to the COVID-19 pandemic, online pharmacies boost up the market share as well and anticipated to emerge as the fastest-growing segment in the market. The convenience of drugs, easy availability, and others are augmenting the growth of online pharmacies during the forecast period.

Top Major Players

Major key players operating in UK Cystic Fibrosis (CF) markets are Vertex Pharmaceuticals Incorporated, AbbVie Inc., Novartis AG, Gilead Sciences Inc., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson, and others. Four branded drugs; Kaftrio (triple combination therapy), Symkevi, Kalydaco, and Orkambi currently marketed by Vertex Pharmaceuticals Incorporated are the best medication drugs trusted by over 90% of the patients affected by cystic fibrosis in the UK will foster the market share during the forecast period.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/139896/

The report covers the competitive analysis of the market. As the demand is driven by a buyer’s paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global United Kingdom Cystic Fibrosis Therapeutics Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global United Kingdom Cystic Fibrosis Therapeutics Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the United Kingdom Cystic Fibrosis Therapeutics market
Chapter 2: Exclusive Summary – the basic information of the United Kingdom Cystic Fibrosis Therapeutics Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the United Kingdom Cystic Fibrosis Therapeutics
Chapter 4: Presenting the United Kingdom Cystic Fibrosis Therapeutics Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the United Kingdom Cystic Fibrosis Therapeutics market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/139896/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the United Kingdom Cystic Fibrosis Therapeutics Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client’s disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.

Latest news
Related news